10:50 AM EST, 11/10/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our 12-month price target by $3 to $75 using a forward P/E of 12x our 2026 EPS view of $6.29 (raised by $0.16), in line with historical averages. We lift our 2025 EPS estimate by $0.15 to $6.02. Q3 sales rose 0.7% Y/Y (+2.7% on an organic basis), reflecting positive performance from all segments, primarily in the Dental Solutions and Health Information Systems (HIS) segments. Sales by segment: MedSurg (58% of Q3 sales) +2%, Dental Solutions (16%) +8.4%, Health Information Systems (16%) +6, Purification & Filtration (6%) -29%, and Other (4%) -5%. We note SOLV divested its P&F segment in September. Adj. operating margin declined 220 bps Y/Y to 20.6%, driven by tariffs and higher operating expenses. We believe the divestiture of P&F will allows concentrated investment in higher-margin core health care businesses. However, we keep our Hold view as challenges are likely to include higher opex as it ramps up investment to build out corporate functions as a stand-alone entity and to support its growth strategy.